FindTrial
Sign In

Relationship between Renal function and pharmacogenetics on plasma level of direct oral anticoagulants (DOACs)

The impact of renal function and pharmacogenetics on plasma level of direct oral anticoagulants (DOACs) in Chinese patients with renal impairment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075841
Enrollment
Unknown
Registered
2023-09-18
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Dabigatran, rivaroxaban, apixaban and edoxaban :N/A

Sponsors

Department of Pathology, University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old 2. Receiving any DOACs (dabigatran, rivaroxaban, apixaban and edoxaban) for atrial fibrillation 3. Follow up in out-patient clinic in Queen Mary Hospital

Exclusion criteria

Exclusion criteria: 1. Age <18 years old 2. Patients who are followed up irregularly in out-patient clinic in Queen Mary Hospital 3. Clinical information is incomplete 4. Non-Chinese

Design outcomes

Primary

MeasureTime frame
Plasma DOACs level;—

Secondary

MeasureTime frame
Rate of bleeding complications;Rate of recurrent ischaemic/thromboembolic events;—

Countries

China

Contacts

Public ContactDr Sin Chun Fung

Department of Pathology, School of Clinical Medicine, University of Hong Kong

scf185@pathology.hku.hk+852 2255 3173

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026